Skip to main content

VUB spin-off Precirix NV enters into alliance with 3P Biopharmaceuticals

  • August 17, 2021

Precirix NV, a clinical-stage biotechnology company developing novel radiopharmaceuticals in oncology, and 3P Biopharmaceuticals S.L.U. (3P), a leading CDMO based in Spain specializing in process development and GMP manufacturing of biological products, have signed an agreement for the clinical manufacturing of a camelid single domain antibody fragment (sdAb), the backbone of Precirix’ next product candidate to enter the clinic.

Read more